Blood Cancer Journal

Article	Citations
CAR-T cell therapy: current limitations and potential strategies	1045
Acute myeloid leukemia: current progress and future directions	354
Multiple myeloma current treatment algorithms	197
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma	140
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)	135
New directions for emerging therapies in acute myeloid leukemia: the next chapter	106
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies	105
CAR T-cell therapy in multiple myeloma: more room for improvement	103
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment	98
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study	96
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia	95
Acute promyelocytic leukemia current treatment algorithms	90
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies	89
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report	85
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups	84
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia	82
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage	79
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm	79
Extramedullary disease in multiple myeloma: a systematic literature review	78
Chromosome 1q21 abnormalities in multiple myeloma	74
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm	72
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma	70
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma	65
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study	64
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response	64

Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study	61
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis	57
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up	56
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality	55
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)	55
Core binding factor acute myelogenous leukemia-2021 treatment algorithm	53
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis	53
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia	52
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life	50
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy	50
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma	50
Genetic and epigenetic determinants of diffuse large B-cell lymphoma	49
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab	49
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis	47
Extramedullary disease in multiple myeloma	47
Diffuse large B-cell lymphoma: new targets and novel therapies	46
A simple additive staging system for newly diagnosed multiple myeloma	44
Management of chronic myeloid leukemia in 2023 – common ground and common sense	41
Comprehensive Review of AL amyloidosis: some practical recommendations	41
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantati	41
Global burden of hematologic malignancies and evolution patterns over the past 30 years	40
Immune-based therapies in the management of multiple myeloma	40
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden	39
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera	39
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia	38
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment	38
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study	38
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results	37
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis	37
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis	37
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study	37
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)	36
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse	35
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML	34
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements	34
Differentiation therapy for myeloid malignancies: beyond cytotoxicity	33
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo	32
“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience	32
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial	32
A clinical perspective on plasma cell leukemia; current status and future directions	32
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions	31
Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia	31
Genomic insights into the pathogenesis of Epstein–Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing	31
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine	31
Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma	31
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel	31
Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma	30
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07	30
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program	30
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia	30

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden	30
Mutations and thrombosis in essential thrombocythemia	29
Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma	29
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study	29
EVI1 dysregulation: impact on biology and therapy of myeloid malignancies	29
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab	29
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy	28
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation	28
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma	28
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice	28
Impact of COVID-19 in patients with multiple myeloma based on a global data network	28
Financial toxicity in hematological malignancies: a systematic review	27
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program	27
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma	27
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021	27
Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center	26
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review	26
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia	26
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points	26
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study	25
Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019	25
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19	25
Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression	24
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML	24
Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy	24
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study	24
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells	24
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication	23
Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies	23
Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia	23
Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities	23
Smoldering multiple myeloma current treatment algorithms	23
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients	23
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee	23
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients	22
Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients	22
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia	22
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib	22
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients	22
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update	22
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study	22
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib	21
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies	20
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)	20
Cutaneous manifestations of monoclonal gammopathy	20
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma	20
Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia	20
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis	20
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review	19
Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms	19
Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera	19
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients	19
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis	19
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy	19
Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells	18
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018	18
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins	18
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement	18
FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome	18
Genomic characterization of functional high-risk multiple myeloma patients	18
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)	18
Infectious complications of bispecific antibody therapy in patients with multiple myeloma	17
Preclinical development of CD126 CAR-T cells with broad antitumor activity	17
High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma	17
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma	17
Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota	17
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL	17
Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism	16
Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia	16
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	16
HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias	16
Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis	16
Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients	16
Therapeutic targeting of the inflammasome in myeloid malignancies	16
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients	16
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome	15
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia	15
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma	15
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma	15
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial	15

Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT	15
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation	15
Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia	15
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy	15
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma	14
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies	14
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma	14
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial	14
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression	14
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation	14
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action	14
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	14
Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany	13
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group	13
Chronic lymphocytic leukemia treatment algorithm 2022	13
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy	13
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry	13
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia	13
Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis	13
Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins	13
4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas	13
Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma	13
Management of patients with lower-risk myelodysplastic syndromes	13
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis	13
Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study	12
Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes	12
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma	12
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation	12
Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants	12
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis	12
Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria	12
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors	12
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX	12
Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features	12
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia	12
Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients	12